Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01721746 · OUTCOME

Overall Survival (OS) by PD-L1 Positive

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) · Source last updated 2022-04-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 96 months

What was measured

Overall Survival (OS) by PD-L1 expression was defined the time between the date of randomization to the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.

Analysis population: All PD-L1 positive evaluable participants for OS

Groups in this outcome

Nivolumab

Nivolumab 3 mg/kg IV over 60 minutes Q2W

Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)

Dacarbazine: 1000 mg/m\^2 IV Q3W Carboplatin: Area under the concentration-time curve (AUC) 6 IV Q3W Paclitaxel: 175 mg/m\^2 IV Q3W

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Nivolumab135
Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)67

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Nivolumab31.44Not reported20.5746.69Not reported
Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)16.72Not reported11.8331.44Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.50
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.01
    estimate Comment
    From unstratified Cox proportional hazard model
    group Description
    PD-L1 Positive
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    param Type
    Hazard Ratio (HR)
    param Value
    0.71
Complete source fields
analyses
  1. ci Lower Limit
    0.50
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.01
    estimate Comment
    From unstratified Cox proportional hazard model
    group Description
    PD-L1 Positive
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    param Type
    Hazard Ratio (HR)
    param Value
    0.71
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        20.57
        upper Limit
        46.69
        value
        31.44
      2. group Id
        OG001
        lower Limit
        11.83
        upper Limit
        31.44
        value
        16.72
denoms
  1. counts
    1. group Id
      OG000
      value
      135
    2. group Id
      OG001
      value
      67
    units
    Participants
description
Overall Survival (OS) by PD-L1 expression was defined the time between the date of randomization to the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    Nivolumab 3 mg/kg IV over 60 minutes Q2W
    id
    OG000
    title
    Nivolumab
  2. description
    Dacarbazine: 1000 mg/m\^2 IV Q3W Carboplatin: Area under the concentration-time curve (AUC) 6 IV Q3W Paclitaxel: 175 mg/m\^2 IV Q3W
    id
    OG001
    title
    Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)
param Type
MEDIAN
population Description
All PD-L1 positive evaluable participants for OS
reporting Status
POSTED
time Frame
Up to 96 months
title
Overall Survival (OS) by PD-L1 Positive
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice